Showing results (1-10 of 87) with videos related to
Sort By:
Pageof 9
Advances in Clinical Chemistry|August 24, 2024
Neurofilaments in neurologic diseaseChristina Mousele, David Holden, Sharmilee GnanapavanCurrent Topics in Behavioral Neurosciences|December 16, 2014
Developing Biomarkers for MSSharmilee Gnanapavan, Gavin GiovannoniMultiple Sclerosis and Related Disorders|April 17, 2015
Neural cell adhesion molecules in brain plasticity and diseaseSharmilee Gnanapavan, Gavin GiovannoniEuropean Journal of Neurology|May 26, 2022
The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosisAshok Adams, William Tilden, Jonathan Bestwick, et al.Multiple Sclerosis and Related Disorders|May 21, 2026
Evaluating the feasibility of a remote sampling method for neurofilament light chain measurements in Multiple SclerosisPanagiotis Gklinos, Nicola Vickaryous, Brook Huxford, et al.Journal of Neurology|March 29, 2011
Surviving stiff-person syndrome: a case reportSharmilee Gnanapavan, Angela Vincent, Gavin GiovannoniMultiple Sclerosis and Related Disorders|June 5, 2025
The practical uses of serum neurofilament light chain as a biomarker in multiple sclerosisJada Coker, Anisha Doshi, Sharmilee GnanapavanMultiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Science is 1% inspiration and 99% biomarkersNicolas Dubuisson, Fabiola Puentes, Gavin Giovannoni, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 12, 2025
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling studyTimothy Jamieson, Florian Tomini, Sharmilee Gnanapavan, et al.Multiple Sclerosis and Related Disorders|June 14, 2021
Can rheumatologists stop causing demyelinating disease?David Baker, Charalambos Hadjicharalambous, Sharmilee Gnanapavan, et al.Pageof 9